soul trial oral semaglutide cardiovascular outcomes results 2025 nejm New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Oral Semaglutide and Cardiovascular Outcomes

Glutathione is given intravenously because this route delivers the antioxidant directly into the bloodstream, bypassing digestive breakdown that destroys nearly all of an oral dose

The lipid benefits of GLP-1 therapy should be viewed as complementary rather than alternative to evidence-based lipid-lowering treatment

After washing three times with TBST, cells were incubated with fluorophore-conjugated secondary antibodies in TBST for 1 h at room temperature

Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease

J.SmithK

Naturally increasing GLP-1 and GIP hormones with GLP-1 Boost harmonizes with your bodys natural production of these hunger hormones and promotes healthy weight loss management